Massachusetts Hospitals Turn to Court Over Lilly’s 340B Data شرط
Five Massachusetts hospitals have sued Eli Lilly after the company cut off 340B drug discounts when they declined to hand over patient claims data through a third-party platform. The complaint, filed Oct. 27 in the U.S. District Court for the District of Massachusetts, places a high-stakes dispute over drug pricing, data privacy and hospital finance squarely in federal court. At issue is whether a manufacturer can condition access to the 340B ceiling price on submission of claims-level information that hospitals say should remain protected.
The plaintiffs are Massachusetts General Hospital, Brigham and Women’s Hospital, North Shore Medical Center, also known as Salem Hospital, UMass Memorial Medical Center and UMass Memorial Health-Harrington Hospital. They allege Lilly violated Massachusetts consumer protection law and was unjustly enriched. The hospitals describe the conflict as “corporate extortion,” but they are careful to say they are not asking the court to run the 340B program or replace the Health Resources and Services Administration. Their theory is narrower: Lilly’s conduct, they argue, independently violates state law.
Claims Data, HIPAA, and the Pricing Condition
Lilly’s policy, adopted in January, required 340B hospitals to submit claims data on drugs dispensed to patients, including in-house pharmacy and medical claims, through the 340B ESP platform as a condition of receiving the 340B ceiling price. The company later gave hospitals five business days to comply or lose pricing. When the hospitals refused, Lilly began denying discounts to noncompliant institutions starting June 18.
The hospitals say the requested information is protected health information under HIPAA. They argue that the expert opinion attached to the platform does not prove the data will remain de-identified, and they contend the structure leaves open the possibility that information could be re-identified once it reaches Lilly. Their objections also extend to the platform’s terms of use, which grant Lilly and the platform a license to use the data and cap the platform owner’s liability at $100.
A single pricing rule can reshape an entire safety-net budget when it reaches the bedside through oncology, neurology and hospital infusion services.
Duplicate Discount Concerns Collide With Hospital Privacy Arguments
Lilly has said its goal is to prevent duplicate discounts, the long-standing concern that a drug could receive overlapping rebates through Medicaid and 340B. The hospitals reject that rationale as pretextual, arguing that HRSA already has audit and dispute resolution mechanisms in place. In their view, a manufacturer cannot unilaterally rewrite the conditions of access to a federal pricing program by imposing a private data gatekeeping system.
That dispute carries direct clinical consequences even though it is framed as a pricing and privacy case. Hospitals use 340B savings to offset uncompensated care, subsidize outpatient services and support community health programs that are rarely reimbursed at cost. When a manufacturer cuts off those discounts, the financial pressure does not remain abstract. It can filter into staffing decisions, service lines, medication access and the volume of uncompensated care a hospital can absorb.
Financial Exposure at Major Academic Medical Centers
The complaint describes substantial losses tied to the policy. UMass Memorial says the change will create annualized overpayments of at least $20 million. Massachusetts General Brigham hospitals estimate they will lose tens of millions of dollars in savings each year. Those figures are tied to individual drug purchases as well, which gives the dispute a concrete and immediate character rather than a theoretical one.
Mass General says it overpaid about $2,478 for a single package of the cancer drug Cyramza. Brigham says it overpaid about $200 for a package of the Alzheimer’s drug Kisunla. Such examples show how a pricing denial can affect both specialty oncology therapy and newer neurologic treatment, where even one purchase can become materially more expensive once 340B access disappears.
The hospitals also anchored their complaint in the size of the charitable work they say the program helps support. UMass Memorial provided $413 million in uncompensated care in fiscal 2025, while Mass General, Brigham and Salem together provided more than $800 million in charity care and health-related services, according to the complaint. The financial model behind 340B is not peripheral to these institutions; it is part of how they sustain care for patients who cannot pay full freight.
Injunctive Relief and Broader Pressure on Lilly
The hospitals are seeking preliminary and permanent injunctions against Lilly’s policy and its loss of 340B pricing, along with compensatory damages, two to three times damages under state law, restitution and attorneys’ fees. They have also demanded a jury trial. The requested relief reflects both the scale of the financial dispute and the hospitals’ belief that an immediate court order is necessary to stop further losses while the case proceeds.
This is not the only challenge to Lilly’s approach. Tampa General Hospital and Mary Hitchcock Memorial Hospital have already brought related cases in federal court, although neither judge has ruled. Missouri’s attorney general also sent Lilly a cease-and-desist letter over the policy. The parallel actions increase the pressure on the company’s position and suggest that the legal fight over claims data may broaden beyond Massachusetts.
For hospitals that rely on 340B discounts to preserve charity care, the case turns on a simple but consequential question: whether access to a federal drug pricing program can be conditioned on sharing claims-level data through a private platform built outside the traditional HRSA enforcement structure. Lilly’s next move will matter, but the complaint already makes clear how much money, privacy concern and operational strain are now tied to a single pricing policy.